Adam MD - MyMD Pharmaceuticals Chief Officer
| MYMDDelisted Stock | USD 1.82 0.02 1.09% |
Insider
Adam MD is Chief Officer of MyMD Pharmaceuticals
| Age | 56 |
| Phone | (856) 848-8698 |
| Web | https://www.mymd.com |
MyMD Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5046) % which means that it has lost $0.5046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0136) %, meaning that it created substantial loss on money invested by shareholders. MyMD Pharmaceuticals' management efficiency ratios could be used to measure how well MyMD Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.MyMD Pharmaceuticals currently holds 48.87 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. MyMD Pharmaceuticals has a current ratio of 2.36, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about MyMD Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Randall Schatzman | Bolt Biotherapeutics | 69 | |
| Marni Kottle | Kronos Bio | N/A | |
| Ryan Kelly | Recursion Pharmaceuticals | N/A | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| Dr AB | Unity Biotechnology | 56 | |
| Michael Secora | Recursion Pharmaceuticals | 41 | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Ron MBA | Nuvectis Pharma | 58 | |
| Roeland Nusse | Surrozen | 74 | |
| Daohong MD | Unity Biotechnology | N/A | |
| Blake Borgeson | Recursion Pharmaceuticals | 42 | |
| Joshua Kazam | Kronos Bio | 47 | |
| Laura Carter | Gossamer Bio | 57 | |
| Calvin MD | Surrozen | N/A | |
| Audrey MD | NovaBay Pharmaceuticals | 65 | |
| Jamie MD | Unity Biotechnology | 66 | |
| JeanPierre Sommadossi | Atea Pharmaceuticals | 68 | |
| Prof MD | Lyell Immunopharma | N/A | |
| Wang Xu | NovaBay Pharmaceuticals | 36 | |
| Mark Newman | GeoVax Labs | 69 | |
| Benjamin MS | Recursion Pharmaceuticals | 41 | |
Management Performance
| Return On Equity | -1.01 | |||
| Return On Asset | -0.5 |
MyMD Pharmaceuticals Leadership Team
Elected by the shareholders, the MyMD Pharmaceuticals' board of directors comprises two types of representatives: MyMD Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MyMD. The board's role is to monitor MyMD Pharmaceuticals' management team and ensure that shareholders' interests are well served. MyMD Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MyMD Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ian CPA, Interim Officer | ||
| MD Chapman, Chief President | ||
| Katherine Whartenby, Chief Board | ||
| Paul Esq, Exec Counsel | ||
| Adam MD, Chief Officer | ||
| Mitchell MD, Chief President |
MyMD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MyMD Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.01 | |||
| Return On Asset | -0.5 | |||
| Current Valuation | 2.99 M | |||
| Shares Outstanding | 2.37 M | |||
| Shares Owned By Insiders | 6.61 % | |||
| Shares Owned By Institutions | 6.62 % | |||
| Number Of Shares Shorted | 263.62 K | |||
| Price To Book | 0.46 X | |||
| EBITDA | (17.12 M) | |||
| Net Income | (4 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |